Management of Invasive Squamous Cell Carcinomas of the Conjunctiva

Autor: Celia Maschi, Stéphanie Baillif, Juliette Thariat, Sandra Lassalle, Alexandra Santoni, Jean-Pierre Caujolle, Joel Herault, Julia Salleron, M. Peyrichon
Přispěvatelé: ARCHADE (Advanced Resource Centre for HADrontherapy in Europe), Département de biostatistiques [ICL Alexis Vautrin], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER-UNICANCER
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
medicine.medical_specialty
Conjunctiva
Mitomycin
[SDV]Life Sciences [q-bio]
Cell
Microscopy
Acoustic
Patient characteristics
Conjunctival Neoplasms
Ophthalmologic Surgical Procedures
Lower risk
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Proton Therapy
Humans
Basal cell
Neoplasm Invasiveness
030304 developmental biology
Aged
Retrospective Studies
0303 health sciences
Antibiotics
Antineoplastic
business.industry
Middle Aged
medicine.disease
Combined Modality Therapy
eye diseases
3. Good health
stomatognathic diseases
Ophthalmology
medicine.anatomical_structure
Bulbar conjunctiva
Dysplasia
Cryotherapy
030221 ophthalmology & optometry
Carcinoma
Squamous Cell
Female
Neoplasm Recurrence
Local
business
Ocular surface
Tomography
Optical Coherence
Zdroj: American Journal of Ophthalmology
American Journal of Ophthalmology, Elsevier Masson, 2019, 200, pp.1-9. ⟨10.1016/j.ajo.2018.11.024⟩
ISSN: 0002-9394
Popis: Ocular surface squamous neoplasia includes a spectrum of diseases from dysplasia to invasive squamous cell carcinoma (SCC) of the conjunctiva. Whether the degree of invasion influences outcomes is debated. We evaluated the outcomes and management of conjunctival carcinomas defined as ≤0.2 mm invasion of the chorion (microinvasive; miSCC) or over (SCC).Retrospective case series.Clinical, tumor, and therapeutic characteristics and outcomes were collected for consecutive patients with histology-proven invasive conjunctival miSCC/SCC treated between 2002 and 2017.Patients were 70% men, ≥70 years old (56%), with carcinomas of the bulbar conjunctiva (83.0%). Limbal, corneal, and/or scleral involvement were present in 70.4%, 42.6%, and 27.8%, respectively. Patient characteristics, tumor characteristics, and no-touch surgery rates were similar between the 39 SCC and 15 miSCC. However, mitomycin was performed in 93.3% and 20.5% of miSCC and SCC, respectively (P.001). Proton therapy was performed in 0% and 92.0% of miSCC and SCC, respectively (P.001). SCC received mitomycin in case of tumoral resection margins, respectively (P = .018). The 24-month incidence of local relapse was 14.8%, including 20% and 12% for miSCC and SCC, respectively (P = .079). Irradiation was the only prognostic factor associated with a lower risk for local relapse (hazard ratio [0.25]; P = .045). There were 2 cancer-related deaths (2%). Mild/moderate anterior segment complications occurred in one third of the patients.miSCC had slightly worse relapse rates compared with SCC. Postoperative proton therapy, performed in SCC only, was associated with a lower risk for relapse.
Databáze: OpenAIRE
Externí odkaz: